1Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
2Institute of Experimental Botany, ASCR, Vídeňská 1083, 142 20 Prague 4, Czech Republic
3Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic

4Institute of Organic Chemistry and Biochemistry, ASCR, Flemingovo n. 2, 166 10 Prague 6, Czech Republic
5Department of Solid State Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
6Institute of Experimental Medicine, ASCR, Vídeňská 1083, 142 20 Prague 4, Czech Republic
7Charles University, Faculty of Medicine in Pilsen, Alej Svobody 76, 323 00 Pilsen, Czech Republic

  1. Corresponding author email

This article is part of the Thematic Series "Lipids: fatty acids and derivatives, polyketides and isoprenoids".

Guest Editor: J. S. Dickschat
Beilstein J. Org. Chem. 2017, 13, 1316–1324. https://doi.org/10.3762/bjoc.13.128
Received 20 Feb 2017, Accepted 20 Jun 2017, Published 04 Jul 2017

Abstract

Like thapsigargin, which is undergoing clinical trials, trilobolide is a natural product with promising anticancer and anti-inflammatory properties. Similar to thapsigargin, it has limited aqueous solubility that strongly reduces its potential medicinal applications. The targeted delivery of hydrophobic drugs can be achieved using liposome-based carriers. Therefore, we designed a traceable liposomal drug delivery system for trilobolide. The fluorescent green-emitting dye BODIPY, cholesterol and trilobolide were used to create construct 6. The liposomes were composed of dipalmitoyl-3-trimethylammoniumpropane and phosphatidylethanolamine. The whole system was characterized by atomic force microscopy, the average size of the liposomes was 150 nm in width and 30 nm in height. We evaluated the biological activity of construct 6 and its liposomal formulation, both of which showed immunomodulatory properties in primary rat macrophages. The uptake and intracellular distribution of construct 6 and its liposomal formulation was monitored by means of live-cell fluorescence microscopy in two cancer cell lines. The encapsulation of construct 6 into the liposomes improved the drug distribution in cancer cells and was followed by cell death. This new liposomal trilobolide derivative not only retains the biological properties of pure trilobolide, but also enhances the bioavailability, and thus has potential for the use in theranostic applications.

Keywords: BODIPY conjugates; cancer targeting; drug delivery; liposomes; natural compounds; sesquiterpene lactone trilobolide

Introduction

Targeted (smart) drug delivery is a method for specific delivering of an active compound preferentially to some cells or tissues in the human body. This approach has become the key issue for surpassing the bottleneck of drug discovery. With the advent of new technologies and deeper understanding of the biological processes, the concept of specific targeting has become one of the most attractive directions in the field of biomedicine. Specific drug targeting can be achieved by using, for example, antibodies, peptides, polyethylene glycol polymers, and last but not least, liposomes, which have been nowadays extensively investigated [1,2]. In general, liposomes are employed in order to enhance the therapeutic index of an applied drug by improvement of drug absorption, prolonging its biological half-life or decreasing its metabolism [3].

Since “seeing is believing”, it is strongly desired to not only target a drug to the disease-affected tissue, but also image its localization and possibly its mechanism of action directly on the given site. Based on this approach, multimodal agents delivered using a vehicle containing a drug capable of both imaging and curing were developed [4]. A meaningful information about biomolecule/drug localization and action can be gained employing fluorescence imaging, since it provides non-invasiveness, sensitivity and good spatio-temporal resolution altogether [5]. From the plethora of known fluorescent compounds, there are widely used small organic fluorophores, such as BODIPY dyes.

BODIPYs are fluorescent dyes based on the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene scaffold, which have recently experienced increased attention in chemistry [6-10] and life science applications [11-13]. On the grounds of high fluorescence quantum yield, narrow spectral characteristics, and sufficient chemical stability, BODIPYs have been utilized for example as laser dyes, tags of small organic molecules [14-16], drugs [17], cell organelle markers, for antibody, peptide and nucleic acid labelling [18-20], for pH [21], metal [22,23] and redox potential sensing (well-reviewed in Boens et al. [24]), as well as for the development of photodynamically active agents [25,26].

In this work, we describe the synthesis and application of a fluorescent construct (further called construct 6, depicted in Scheme 1) based on a green-emitting BODIPY dye and trilobolide–cholesterol (Tb-ChL) in a liposome formulation. Trilobolide (Tb, Figure 1) is a potent natural compound of the sesquiterpene lactone class, which causes cell death via depleting intracellular Ca2+ ion stores by the irreversible inhibition of sarco-/endoplasmic reticulum Ca2+-ATPase (SERCA) already at nanomolar concentrations [27-30]. In our recent study, we reported the localization of fluorescent Tb-BODIPY conjugates in the endoplasmic reticulum of a number of cancer cell lines [31]. Besides that, Tb is of high interest also for the fact that it induces high production of nitric monoxide (NO) which has an immunomodulating effect on rat peritoneal cells [32]. We documented in [31] that Tb, prepared as a fluorescent conjugate with green-emitting BODIPY, induced a dose-dependent NO production in primary rat macrophages. The potency of the fluorescent Tb to express inducible NO and cytokine secretion was shifted to a low micromolar range in comparison to the submicromolar activity of Tb itself.

The introduction of cholesterol (ChL) in the proposed structure is based on its routine exploitation in production of artificial liposome vehicles. Incorporation of ChL into liposomes was shown to ‘tighten’ the fluid bilayers, and thus, to reduce the leakage of an active content from the liposomes [1]. Taken together, a construct 6 probe, containing Tb, ChL and BODIPY, represents a well-defined traceable system with a potentiated ability to assemble into liposomal systems.

Results and Discussion

Chemistry

In this work, Tb was connected to a pegylated BODIPY building block containing ChL. This way obtained construct 6 was used as a component for liposomal formulation. The syntheses of some of the employed molecules were previously described [24,27,28], their structures are shown in Figure 1.

[1860-5397-13-128-1]

Figure 1: Chemical structures of the basic compounds used in this study.

The synthesis of a BODIPY-based building block is displayed in Scheme 1, part A. Methyl 4-iodo-L-phenylalaninate hydrochloride was prepared by the reaction of 4-iodo-L-phenylalanine with thionyl chloride in MeOH in quantitative yield [33]. The successive acylation of the α-amino group with 5-azidovaleric acid catalyzed by T3P (propylphosphonic anhydride) in the mixture of pyridine and AcOEt gave azidoterminated product 1 in 70% yield. Alkaline hydrolysis of methyl ester 1 with aqueous LiOH in THF and subsequent Suzuki cross-coupling with BODIPY-BA [34] catalyzed by Pd(PPh3)4 and K2CO3 in a mixture of toluene/MeOH/water provided the fluorescent building block 3 in 88% yield.

[1860-5397-13-128-i1]

Scheme 1: Synthesis of the BODIPY building block (part A) and construct 6 (part B).

Sequential connection of other functional components of the target compound is shown in Scheme 1, part B. Propargyl-ChL [35] was introduced into Huisgen copper-catalyzed 1,3-dipolar cycloaddition [36] (CuAAC) with BODIPY 3. This microwave-assisted reaction catalyzed by CuSO4·5H2O, sodium ascorbate and a catalytic amount of TBTA (tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine) [37] in DMF gave a cholesterol-containing clickate 4 in 49% yield. The pegylation of 4 with amino-PEG4-alkyne in the presence of EDCI (N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride), 4-DMAP (4-dimethylaminopyridine) and HOBt (N-hydroxybenzotriazole) in DMF provided an alkyne-terminated intermediate 5 in excellent yield (92%). Finally, CuAAC cycloadition of 5 and Tb-N3VA [31] gave the target fluorescent construct 6 in good yield (84%).

The absorbance and fluorescence emission spectra of compounds 36 are depicted in Figure 2.

[1860-5397-13-128-2]

Figure 2: Absorbance and fluorescence spectra of compounds 36. UV spectra (part A) were recorded with a concentration of 10 μM in DCM and fluorescence spectra (part B) with a concentration of 0.1 μM in DCM using an excitation wavelength of 475 nm. A typical Stokes shift (10 nm) is demonstrated for construct 6 (part C).

Compounds 36 showed absorption and emission maxima at 503 and 513 nm (excitation at 475 nm), respectively. The molar extinction coefficients of 36 in DCM ranged from 45,000 to 58,000 L·mol−1·cm−1. The purity of the target construct 6 was determined by HPLC–MS and proved to be ≥95% (Supporting Information File 1, section 5.3, Figure S15). Thereafter, construct 6 was used for liposomal formulation and biological experiments, in which the immunomodulatory, delivery and anticancer potential was evalueated.

Nitric oxide release in primary macrophages

NO (nitric oxide) is one of the most important effector molecules in the repertoire of non-specific immune defence mechanisms. This molecule is produced by macrophages and the antimicrobial and antiparasitic properties of NO have been well described [38]. Currently, the role of NO as a mediator between chronic inflammation and carcinogenesis is intensively studied [39]. The expression of inducible NO is under control of a number of cytokines. Alternatively, lipopolysaccharide (endotoxin) is known as strong inducer of NO in macrophages. Since it is known that sesquiterpene lactones, Tg, Tb, as well as Tb derivatives [31], possess strong stimulating activity for NO production by immune cells [40,41], we examined whether construct 6, also based on Tb, exhibits similar immunobiological properties. The production of NO was evaluated after 24 h of cultivation of primary rat macrophages in the presence of increasing concentrations of Tb and construct 6. In this study, we observed the typical activity of Tb to induce NO production in rodent macrophages which started below 0.1 µM Tb and reached an NO production of 50 µM in the presence of 4 µM Tb (the highest concentration tested, Figure 3).

[1860-5397-13-128-3]

Figure 3: NO production in primary rat macrophages. The cells were treated with Tb, compounds 4, 5, and Tb-construct 6 for 24 h with or without lipopolysaccharide (LPS, 100 pg·mL−1). The results represent the mean ± SEM of 2 independent experiments, n = 4. Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001; black*: compounds are significantly different from untreated cells, red*: the compound is significantly different from LPS-treated cells.

The tested construct 6 induced moderate dose-dependent NO induction (methods in Supporting Information File 1, sections 4.3 and 4.4). The significant increase of NO to 21 µM was observed only at the highest concentration of 100 µM of construct 6 (*P < 0.05). We also investigated an eventual synergistic effect of construct 6 and lipopolysaccharide (LPS) in macrophage immunomodulation. To activate the macrophages, only a low concentration of an immunostimulator (LPS, 100 pg·mL−1) was used. In the presence of LPS, the dose-dependent curve for NO production was running higher and it was in parallel with the curve of non-stimulated cells. The synergistic effect of construct 6 with LPS on increased NO production was detected at 40 µM concentration of Tb-construct 6, and it was significantly pronounced at 100 µM of construct 6 (*P < 0.05 vs LPS), upon which the level of NO reached 30 µM concentration. As expected, no effect on NO synthesis was found for 4 and 5 BODIPYs-ChL derivatives not containing Tb. No changes were detected in cell viability (WST-1 assay) for compounds 4, 5, and 6 (data not shown). From these and previous findings [30,31], we can summarize that the reduced immunomodulatory activity of Tb construct 6 is given by its high molecular weight (MW equal to 1814) in comparison to Tb (MW equal to 522), and overall shape of the molecule. Further, cholesterol is one of the basic natural components of eukaryotic cells, thus some portion of construct 6 could be fixed in plasma membrane, which decreases the possibility of manifesting the known biological effects of Tb inside cells [42].

Liposome preparation and characterization

Liposomes were prepared by a reverse-phase evaporation method followed by homogenization (Supporting Information File 1, section 2). Dipalmitoyl-3-trimethylammonium-propane (DPTAP), phosphatidylethanolamine (DOPE) and ChL were used for implementation of fluorescent construct 6 into liposomal formulation (ratio 4:4:1:1, respectively). A hydrophobic film prepared by evaporation of a lipid–chloroform solution was hydrated with physiological solution. The desired unilamellar vesicles were obtained by homogenization of the dispersion through a 100 nm pore size polycarbonate filter. Characterization of the prepared liposomes with incorporated construct 6 was performed by atomic force microscopy (AFM) analysis in a tapping mode in 2D and 3D arrangement, see Figure 4 (Supporting Information File 1, section 3).

[1860-5397-13-128-4]

Figure 4: Atomic force microscopy images of liposomes, 5 µm area: A) 2D image, B) 3D image (Ra = 2.4 nm); 2 µm area: C) 2D image, D) 3D image (Ra = 2.6 nm). Ra represents the arithmetic average of the deviations from the centre plane of the sample.

We confirmed the successful preparation of liposomes, the average size of which was 150 nm in width and 30 nm in height. The larger dimension of the liposomes in width, than expected, was probably caused by their adhesion to the glass surface, which was on the other hand necessary in order to perform the AFM analysis. The values of average roughness described in the Figure 4 for both (2 × 2) and (5 × 5) μm2 are almost similar, therefore the uniformity of prepared liposomes over the surface was proven (no significant differences caused by change in the surface structure). It was confirmed, on the basis of surface roughness for both scanning areas and the evaluation of height and width of globular structures, that prepared liposomes were uniform in shape (high variability in shape or inhomogeneous peak structure would extensively increase the roughness value) and the cover over the surface was also homogeneous.

Live-cell imaging of construct 6 and its liposomal formulation

The potency of the fluorescent construct Tb-ChL and BODIPY and its liposome derivative to enter cancer cells was tested by live-cell fluorescence microscopy using two human cell line models: cells were derived from osteosarcoma (U-2 OS) and cervical carcinoma (HeLa).

Inside U-2 OS cells, construct 6 was localized from 200 nM concentration already after 1 h of incubation, the fluorescent signal was of dot-like character and persisted for at least 48 h until which, the intracellular localization was followed (Figure 5).

[1860-5397-13-128-5]

Figure 5: Panel of images from live-cell fluorescence microscopy: intracellular localization of construct 6 in U-2 OS cells after 48 h of incubation: A) 200 nM; C) 500 nM concentration of construct 6; B) and D) merges of A and C with bright field images of U-2 OS cells, respectively.

A similar situation was observed in HeLa cells (Supporting Information File 1, Figure S17), in which the construct 6 was also internalized and its distribution resembled the structure of the endoplasmic reticulum as well as partially the cell membrane.

In the case of liposomes containing construct 6, intracellular uptake was detected already at 43 nM concentration after 1 h of incubation with U-2 OS cells (Supporting Information File 1, Figure S16), on which they were bound at the plasma membrane. After 2 h of incubation, there were two populations of cells with liposomes bound either on the plasma membrane or inside the cells (Figure 6).

[1860-5397-13-128-6]

Figure 6: Panel of images from live-cell fluorescence microscopy: intracellular localization of liposomes with construct 6 (250 nM) in U-2 OS cells after 2 h of incubation: A, D) bright field; B, E) construct 6 in liposomes; C, F) merged images of A and B and D and E.

The intracellular localization of liposomes was further pronounced with increased concentration up to 1.25 µM (Supporting Information File 1, Figure S18) after 2 h of incubation. With prolonged time (7 h), the U-2 OS cells were disrupted and underwent cell death (Supporting Information File 1, Figure S18), which could be caused by the release of the active construct 6 from the liposomes. Further tests are necessary to confirm this hypothesis.

Conclusion

In summary, in order to develop a drug delivery system for potential theranostic applications, we prepared a submicron liposome-based formulation of a cytotoxic agent, sesquiterpene lactone, trilobolide. More specifically, we synthesized and characterized a fluorescent construct of Tb conjugated to cholesterol and a green-emitting BODIPY dye, which was successfully incorporated into liposomes. The immunomodulatory activity tested in primary rat macrophages revealed significant dose-dependent NO production in the presence of LPS; at 100 µM concentration of construct 6, the level of NO raised up to 30 µM. In further biological evaluation, we found that construct 6 was efficiently localized inside human U-2 OS and HeLa cancer cells. The encapsulation of construct 6 into liposomes resulted in sufficient distribution inside the cancer cells. The intracellular trafficking pattern of liposomes was characterized by two populations: the first one clearly localized on the cell membrane and the other inside the cells. With prolonged time, the population with internalized liposomes was linked to cell death, which might be caused by the release of active construct 6 from liposomes in cells. This study could be useful for further design and optimization of analogous systems for theranostic liposomal drug-delivery applications.

Supporting Information

Supporting Information File 1: Additional information, characterization methods, experimental, analytical data, and supporting images from live-cell fluorescence microscopy.
Format: PDF Size: 3.0 MB Download

Acknowledgements

The authors thank for funding of this research to MŠMT (project MSMT No 20-SVV/2017, and project COST LD15012, a part of the COST Action CM1407) and Czech Science Foundation (GAČR) 14-04329S and the Czech Republic grants no. CZ.2.16/3.1.00/24503, LO1601, LO1304 (National Program of Sustainability). The authors are grateful to Dr. Juraj Harmatha for trilobolide.

References

  1. Allen, T. M.; Cullis, P. R. Adv. Drug Delivery Rev. 2013, 65, 36–48. doi:10.1016/j.addr.2012.09.037
    Return to citation in text: [1] [2]
  2. Pattni, B. S.; Chupin, V. V.; Torchilin, V. P. Chem. Rev. 2015, 115, 10938–10966. doi:10.1021/acs.chemrev.5b00046
    Return to citation in text: [1]
  3. Çağdaş, M.; Sezer, A. D.; Bucak, S. Liposomes as Potential Drug Carrier Systems for Drug Delivery. In Application of Nanotechnology in Drug Delivery; Sezer, A. D., Ed.; InTech., 2014. doi:10.5772/58459
    Return to citation in text: [1]
  4. Kelkar, S. S.; Reineke, T. M. Bioconjugate Chem. 2011, 22, 1879–1903. doi:10.1021/bc200151q
    Return to citation in text: [1]
  5. Liu, Y.; Lok, C.-N.; Ko, B. C.-B.; Shum, T. Y.-T.; Wong, M.-K.; Che, C.-M. Org. Lett. 2010, 12, 1420–1423. doi:10.1021/ol902890j
    Return to citation in text: [1]
  6. Courtis, A. M.; Santos, S. A.; Guan, Y.; Hendricks, J. A.; Ghosh, B.; Szantai-Kis, D. M.; Reis, S. A.; Shah, J. V.; Mazitschek, R. Bioconjugate Chem. 2014, 25, 1043–1051. doi:10.1021/bc400575w
    Return to citation in text: [1]
  7. Verbelen, B.; Boodts, S.; Hofkens, J.; Boens, N.; Dehaen, W. Angew. Chem., Int. Ed. 2015, 54, 4612–4616. doi:10.1002/anie.201410853
    Return to citation in text: [1]
  8. Chong, H.; Lin, H.-A.; Shen, M.-Y.; Liu, C.-Y.; Zhao, H.; Yu, H.-h. Org. Lett. 2015, 17, 3198–3201. doi:10.1021/acs.orglett.5b00875
    Return to citation in text: [1]
  9. Ni, Y.; Lee, S.; Son, M.; Aratani, N.; Ishida, M.; Samanta, A.; Yamada, H.; Chang, Y.-T.; Furuta, H.; Kim, D.; Wu, J. Angew. Chem., Int. Ed. 2016, 55, 2815–2819. doi:10.1002/anie.201511151
    Return to citation in text: [1]
  10. Patalag, L. J.; Jones, P. G.; Werz, D. B. Angew. Chem., Int. Ed. 2016, 55, 13340–13344. doi:10.1002/anie.201606883
    Return to citation in text: [1]
  11. Hölttä-Vuori, M.; Uronen, R.-L.; Repakova, J.; Salonen, E.; Vattulainen, I.; Panula, P.; Li, Z.; Bittman, R.; Ikonen, E. Traffic 2008, 9, 1839–1849. doi:10.1111/j.1600-0854.2008.00801.x
    Return to citation in text: [1]
  12. Osati, S.; Ali, H.; van Lier, J. E. J. Porphyrins Phthalocyanines 2016, 20, 61–75. doi:10.1142/S1088424616300019
    Return to citation in text: [1]
  13. Lv, H.-j.; Zhang, X.-t.; Wang, S.; Xing, G.-w. Analyst 2017, 142, 603–607. doi:10.1039/C6AN02705A
    Return to citation in text: [1]
  14. Li, Z.; Mintzer, E.; Bittman, R. J. Org. Chem. 2006, 71, 1718–1721. doi:10.1021/jo052029x
    Return to citation in text: [1]
  15. Malachowska-Ugarte, M.; Sperduto, C.; Ermolovich, Y. V.; Sauchuk, A. L.; Jurášek, M.; Litvinovskaya, R. P.; Straltsova, D.; Smolich, I.; Zhabinskii, V. N.; Drašar, P.; Demidchik, V.; Khripach, V. A. Steroids 2015, 102, 53–59. doi:10.1016/j.steroids.2015.07.002
    Return to citation in text: [1]
  16. Jurášek, M.; Rimpelová, S.; Pavlíčková, V.; Ruml, T.; Lapčík, O.; Drašar, P. B. Steroids 2015, 97, 62–66. doi:10.1016/j.steroids.2014.10.002
    Return to citation in text: [1]
  17. Fishkin, N. Mol. Pharmaceutics 2015, 12, 1745–1751. doi:10.1021/mp500843r
    Return to citation in text: [1]
  18. Seo, T. S.; Bai, X.; Ruparel, H.; Li, Z.; Turro, N. J.; Ju, J. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 5488–5493. doi:10.1073/pnas.0401138101
    Return to citation in text: [1]
  19. Tram, K.; Twohig, D.; Yan, H. Nucleosides, Nucleotides Nucleic Acids 2011, 30, 1–11. doi:10.1080/15257770.2010.536798
    Return to citation in text: [1]
  20. Ehrenschwender, T.; Wanninger-Weiß, C.; Wagenknecht, H.-A. Nucleic Acids Symp. Ser. 2008, 52, 349–350. doi:10.1093/nass/nrn176
    Return to citation in text: [1]
  21. Ni, Y.; Wu, J. Org. Biomol. Chem. 2014, 12, 3774–3791. doi:10.1039/c3ob42554a
    Return to citation in text: [1]
  22. Niu, L.-Y.; Li, H.; Feng, L.; Guan, Y.-S.; Chen, Y.-Z.; Duan, C.-F.; Wu, L.-Z.; Guan, Y.-F.; Tung, C.-H.; Yang, Q.-Z. Anal. Chim. Acta 2013, 775, 93–99. doi:10.1016/j.aca.2013.03.013
    Return to citation in text: [1]
  23. Feng, L.; Li, H.; Niu, L.-Y.; Guan, Y.-S.; Duan, C.-F.; Guan, Y.-F.; Tung, C.-H.; Yang, Q.-Z. Talanta 2013, 108, 103–108. doi:10.1016/j.talanta.2013.02.073
    Return to citation in text: [1]
  24. Boens, N.; Leen, V.; Dehaen, W. Chem. Soc. Rev. 2012, 41, 1130–1172. doi:10.1039/C1CS15132K
    Return to citation in text: [1] [2]
  25. Kamkaew, A.; Lim, S.-H.; Lee, H. B.; Kiew, L. V.; Chung, L. Y.; Burgess, K. Chem. Soc. Rev. 2013, 42, 77–88. doi:10.1039/C2CS35216H
    Return to citation in text: [1]
  26. Caruso, E.; Banfi, S.; Barbieri, P.; Leva, B.; Orlandi, V. T. J. Photochem. Photobiol., B 2012, 114, 44–51. doi:10.1016/j.jphotobiol.2012.05.007
    Return to citation in text: [1]
  27. Gibbs, J. H.; Zhou, Z.; Kessel, D.; Fronczek, F. R.; Pakhomova, S.; Vicente, M. G. H. J. Photochem. Photobiol., B 2015, 145, 35–47. doi:10.1016/j.jphotobiol.2015.02.006
    Return to citation in text: [1] [2]
  28. Søhoel, H.; Lund Jensen, A.-M.; Møller, J. V.; Nissen, P.; Denmeade, S. R.; Isaacs, J. T.; Olsen, C. E.; Christensen, S. B. Bioorg. Med. Chem. 2006, 14, 2810–2815. doi:10.1016/j.bmc.2005.12.001
    Return to citation in text: [1] [2]
  29. Wictome, M.; Khan, Y. M.; East, J. M.; Lee, A. G. Biochem. J. 1995, 310, 859–868. doi:10.1042/bj3100859
    Return to citation in text: [1]
  30. Jurášek, M.; Džubák, P.; Rimpelová, S.; Sedlák, D.; Konečný, P.; Frydrych, I.; Gurska, S.; Hajdúch, M.; Bogdanová, K.; Kolář, M.; Müller, T.; Kmoníčková, E.; Ruml, T.; Harmatha, J.; Drašar, P. B. Steroids 2017, 117, 97–104. doi:10.1016/j.steroids.2016.08.011
    Return to citation in text: [1] [2]
  31. Jurášek, M.; Rimpelová, S.; Kmoníčková, E.; Drašar, P.; Ruml, T. J. Med. Chem. 2014, 57, 7947–7954. doi:10.1021/jm500690j
    Return to citation in text: [1] [2] [3] [4] [5]
  32. Kmoníčková, E.; Harmatha, J.; Vokáč, K.; Kostecká, P.; Farghali, H.; Zídek, Z. Fitoterapia 2010, 81, 1213–1219. doi:10.1016/j.fitote.2010.08.005
    Return to citation in text: [1]
  33. Yan, J.; Huang, N.; Li, S.; Yang, L.-M.; Xing, W.; Zheng, Y.-T.; Hu, Y. Bioorg. Med. Chem. Lett. 2012, 22, 1976–1979. doi:10.1016/j.bmcl.2012.01.037
    Return to citation in text: [1]
  34. Bai, M.; Huang, J.; Zheng, X.; Song, Z.; Tang, M.; Mao, W.; Yuan, L.; Wu, J.; Weng, X.; Zhou, X. J. Am. Chem. Soc. 2010, 132, 15321–15327. doi:10.1021/ja106637e
    Return to citation in text: [1]
  35. Rega, M.; Jiménez, C.; Rodriguez, J. Steroids 2007, 72, 729–735. doi:10.1016/j.steroids.2007.03.014
    Return to citation in text: [1]
  36. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem., Int. Ed. 2002, 41, 2596–2599. doi:10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4
    Return to citation in text: [1]
  37. Hein, J. E.; Tripp, J. C.; Krasnova, L. B.; Sharpless, K. B.; Fokin, V. V. Angew. Chem., Int. Ed. 2009, 48, 8018–8021. doi:10.1002/anie.200903558
    Return to citation in text: [1]
  38. Mariotto, S.; Menegazzi, M.; Suzuki, H. Curr. Pharm. Des. 2004, 10, 1627–1645. doi:10.2174/1381612043384637
    Return to citation in text: [1]
  39. Rahat, M. A.; Hemmerlein, B. Front. Physiol. 2013, 4, No. 144. doi:10.3389/fphys.2013.00144
    Return to citation in text: [1]
  40. Kmoníčková, E.; Melkusová, P.; Harmatha, J.; Vokáč, K.; Farghali, H.; Zídek, Z. Eur. J. Pharmacol. 2008, 588, 85–92. doi:10.1016/j.ejphar.2008.03.037
    Return to citation in text: [1]
  41. Harmatha, J.; Buděšínský, M.; Vokáč, K.; Kostecká, P.; Kmoníčková, E.; Zídek, Z. Fitoterapia 2013, 89, 157–166. doi:10.1016/j.fitote.2013.05.025
    Return to citation in text: [1]
  42. Tomanová, P.; Rimpelová, S.; Jurášek, M.; Buděšínský, M.; Vejvodová, L.; Ruml, T.; Kmoníčková, E.; Drašar, P. B. Steroids 2015, 97, 8–12. doi:10.1016/j.steroids.2014.08.024
    Return to citation in text: [1]

© 2017 Škorpilová et al.; licensee Beilstein-Institut.
This is an Open Access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (http://www.beilstein-journals.org/bjoc)

 
Back to Article List

Other Beilstein-Institut Open Science Activities

Keep Informed

RSS Feed

Subscribe to our Latest Articles RSS Feed.

Subscribe

Follow the Beilstein-Institut

LinkedIn

Twitter: @BeilsteinInst